EP Patent

EP0021178B1 — Maytansinoids, their production and use

Assigned to Takeda Pharmaceutical Co Ltd · Expires 1984-01-18 · 42y expired

What this patent protects

Novel maytansinoids of the formula: <IMAGE> wherein Y is H or Cl, and R is C2-15alkyl, phenyl-C1-4alkyl, pyridyl-C1-4alkyl, imidazolyl-C1-4alkyl, indolyl-C1-4alkyl, furyl-C1-4alkyl or thienyl-C1-4alkyl, said R group being substituted by hydroxyl, halogen or C1-5alkanoylox…

USPTO Abstract

Novel maytansinoids of the formula: <IMAGE> wherein Y is H or Cl, and R is C2-15alkyl, phenyl-C1-4alkyl, pyridyl-C1-4alkyl, imidazolyl-C1-4alkyl, indolyl-C1-4alkyl, furyl-C1-4alkyl or thienyl-C1-4alkyl, said R group being substituted by hydroxyl, halogen or C1-5alkanoyloxy at its alpha - and/or beta -position, have antimitotic, antitumor and antimicrobial activities.

Drugs covered by this patent

Patent Metadata

Patent number
EP0021178B1
Jurisdiction
EP
Classification
Expires
1984-01-18
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.